Stocklytics Platform
Asset logo for symbol CERE
Cerevel Therapeutics Holdings
CERE40
$44.960.00%$0.00
Asset logo for symbol CERE
CERE40

$44.96

0.00%
Key Stats
Open$44.96
Prev. Close$44.96
EPS-2.73
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range44.96
44.96
52 Week Range19.59
44.99
Ratios
Revenue-
EBITDA Margin %-
EPS-2.73
Fundamentals
RPS-
Gross Profit-
Payout Ratio-
Industry average yield3.25%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

CERE-
US Healthcare Sector-
US Market-
check_circle

CERE / Market

CERE exceeded the US Market which returned -0.68% over the last twenty four hours.
warning

CERE / Healthcare Sector

CERE lose to the US Healthcare sector which returned 1.01% over the last twenty four hours.

Cerevel Therapeutics Holdings (CERE) Statistics

INSTRUMENT_STATISTICS for Cerevel Therapeutics Holdings, Inc. (CERE) provide valuable insights into the stock's performance and valuation metrics. These statistics help investors assess the fundamentals of the company and compare its stock performance to the sector. CERE's valuation metrics give an indication of how the market values the company. This includes metrics such as price-to-earnings ratio (P/E), price-to-sales ratio (P/S), and price-to-book ratio (P/B). These ratios help investors determine if the stock is overvalued or undervalued. CERE's fundamentals, including its revenue per share, enterprise to EBITDA ratio, profit margin, total debt, and gross profit, provide a comprehensive understanding of the company's financial standing and operational efficiency. Investors can analyze these metrics to assess the company's profitability, debt levels, and overall performance compared to its peers. The CEO of Cerevel Therapeutics Holdings, Inc. plays a crucial role in the company's success. Their leadership and strategic decisions impact the company's direction and growth prospects. Overall, understanding CERE's instrument statistics can help investors make informed investment decisions and evaluate the company's potential.
add Cerevel Therapeutics Holdings to watchlist

Keep an eye on Cerevel Therapeutics Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Cerevel Therapeutics Holdings (CERE) stock's performance compared to its sector and the market over the past year?

Over the past year, Cerevel Therapeutics Holdings (CERE) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 19.05%, Cerevel Therapeutics Holdings has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 43.77%, it has fallen short of the market average. This comparison highlights Cerevel Therapeutics Holdings's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Cerevel Therapeutics Holdings (CERE) stock?

The PE ratio for Cerevel Therapeutics Holdings (CERE) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Cerevel Therapeutics Holdings (CERE) stock?

The Earnings Per Share (EPS) for Cerevel Therapeutics Holdings (CERE), calculated on a diluted basis, is -$2.73. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Cerevel Therapeutics Holdings (CERE) stock?

The operating margin for Cerevel Therapeutics Holdings (CERE) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Cerevel Therapeutics Holdings (CERE) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Cerevel Therapeutics Holdings (CERE) is -$484.52M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Cerevel Therapeutics Holdings (CERE) have?

Cerevel Therapeutics Holdings (CERE) has a total debt of $482.3M. The net debt, which accounts for cash and cash equivalents against the total debt, is $47.86M.

Take Your Investments to a Whole New Level